10. REFERENCES


52. Sachdev Yadav. Status of adverse drug reaction monitoring and pharmacovigilance in selected countries. Indian J Pharmacol. 2008;40:S4-S9


74. Lifetime Impacts: Childhood and adolescent mental health, Understanding the lifetime impacts. Report of a seminar organized by the Office of Health Economics and the Mental Health Foundation, April 2004 available from
References


105. 25% in state suffer mental problems’ The times of India. Bangalore Dec 11, 2012, 06.22 AM IST.

106. The ICD-10, Classification of mental and behavioral disorders; Diagnostic criteria for research; World Health Organization: 1993. available at [http://www.who.int/classifications /icd/].


139. Fawad T, Mansoor T, Zarmeneh A, Ameer A.K, Asma T et al. Factors associated with non-adherence among psychiatric patients at a tertiary care
References


dyscariasis induced by psychotropic drugs. Pharmacopsychiatry. 2004;37(1):
70-78.

185. Robert J. Flanagan, Louisa Dunk. Haematological toxicity of drugs used in

186. Bourin M, Briley M. Sedation, an unpleasant, undesirable and potentially
dangerous side-effect of many psychotropic drugs. Hum Psychopharmacol.

187. Del D. Miller. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care

188. S. Kaushik, J.P. Lindenmayer, Anzalee Khan. Management of antipsychotic side
effects. Primary Psychiatry. 2007;14(7):77-82.

189. Leucht S, Wahlbeck K, Hamann J. New generation antipsychotics versus low-
potency conventional antipsychotics: a systematic review and meta-analysis.

190. Madhusoodanan S, Alexenko L, Sanders R, Brenner R. Extrapyramidal
symptoms associated with antidepressants—A review of the literature and an
148-156.

191. Joseph A. Lieberman. Managing anticholinergic side effects. Prim Care


226. WHO definition Safety monitoring of medicinal products: Guidelines for setting up and running a pharmacovigilance centre. The Uppsala Monitoring Centre.


